Provided by Tiger Trade Technology Pte. Ltd.

TuHURA Biosciences, Inc.

1.96
+0.03001.55%
Post-market: 1.960.00000.00%16:10 EDT
Volume:148.97K
Turnover:292.59K
Market Cap:124.61M
PE:-3.61
High:1.99
Open:1.95
Low:1.95
Close:1.93
52wk High:3.43
52wk Low:0.4100
Shares:63.58M
Float Shares:39.66M
Volume Ratio:0.59
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5428
EPS(LYR):-0.6272
ROE:-161.39%
ROA:-58.43%
PB:6.84
PE(LYR):-3.12

Loading ...

TuHURA Biosciences receives U.S. patent for DOR ADC technology

TIPRANKS
·
Oct 05

TuHURA Biosciences Wins US Patent Covering Delta Opioid Receptor Antagonist Cancer Therapies

Reuters
·
Oct 05

Tuhura Biosciences Receives Key U.S. Patent for Its Groundbreaking Delta Opioid Receptor (Dor) Antibody Drug Conjugate (ADC) Technology

THOMSON REUTERS
·
Oct 05

Tuhura Biosciences Draws $650,000 Under Parkview Holdings $50 Million Revolving Credit Facility

Reuters
·
Sep 25

Tuhura Biosciences Draws USD 650,000 from Parkview Holdings Revolving Credit Facility

Reuters
·
Sep 18

TuHURA Biosciences Adopts 2026 Inducement Equity Plan, Reserves 5,000,000 Shares for New-Hire Awards

Reuters
·
Sep 17

TuHURA Biosciences: FDA clears IND for TBS-2025 VISTA-inhibiting antibody

TIPRANKS
·
Sep 14

TuHURA Biosciences Wins FDA IND Clearance for TBS-2025 in mutNPM1 AML Study

Reuters
·
Sep 14

Tuhura Biosciences - Study Expected to Progress to Dose-Optimization Stage After FDA Safety Review

THOMSON REUTERS
·
Sep 14

Tuhura Biosciences Receives FDA "Study May Proceed" Notice and Ind Clearance for the Evaluation of Its Tbs-2025 Vista-Inhibiting Antibody in Molecularly Defined Subsets of Aml and Other Blood-Related Cancers

THOMSON REUTERS
·
Sep 14

Tuhura Biosciences - May Explore Trial Expansion & Accelerated Approval with FDA if Response Rates Encouraging

THOMSON REUTERS
·
Sep 14

TuHURA Biosciences CEO Bianco to Present at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 08

Tuhura Biosciences Draws $1.5 Million from Parkview Holdings Revolving Credit Facility

Reuters
·
Sep 05

Analysts’ Top Healthcare Picks: CVS Health (CVS), TuHURA Biosciences (HURA)

TIPRANKS
·
Aug 27

Tuhura Biosciences Draws $650,000 from Parkview Revolving Credit Facility

Reuters
·
Aug 22

Tuhura Biosciences Holds Annual Shareholder Meeting

Reuters
·
Aug 20

TuHURA Biosciences Price Target Maintained with a $9.00/Share by Citizens

Dow Jones
·
Aug 18

TuHURA Biosciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 15

TuHURA Biosciences Q2 EPS $(0.14) Beats $(0.15) Estimate

Benzinga Earnings
·
Aug 14

Tuhura Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
Aug 14